Advances in the Diagnosis and Treatment of Gastroesophageal Reflux Disease in China

doi:10.3877/cma.j.issn.2095-8765.2024.02.002

Abstract

Abstract:

Gastroesophageal reflux disease (GERD) is one of the most common chronic gastrointestinal disorders. The prevalence of GERD in China is 8.7%. Due to the diverse manifestations, the diagnosis of GERD is a challenge for clinicians. Chinese guideline proposed that patients with Los Angeles grade B/C/D esophagitis or acid exposure time>4% could be diagnosed as GERD. Although acid suppressive therapy is the first-line treatment for GERD, up to 50% of patients did not report effective symptom relief despite medications. Such patients typically undergo endoscopic anti-reflux surgery, but some still need to take anti-reflux medication or even undergo a secondary surgery to control GERD symptoms. This article summarized the current status of diagnosis and treatment of GERD in China, offering valuable insights for clinical physicians.

Key words: Gastroesophageal reflux disease, Diagnosis, Treatment

Qianjun Zhuang, Dianxuan Jiang, Yinglian Xiao. Advances in the Diagnosis and Treatment of Gastroesophageal Reflux Disease in China[J]. Chinese Journal of Gastroesophageal Reflux Disease(Electronic Edition), 2024, 11(02): 75-80.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhwsgflbdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-8765.2024.02.002

https://zhwsgflbdzzz.cma-cmc.com.cn/EN/Y2024/V11/I02/75

Figures/Tables 2

References 31

1	Vakil N, van Zanten SV, Kahrilas P, et al. The montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus [J]. Am J Gastroenterol, 2006, 101(8): 1900-1920; quiz 1943.
2	Lu TL, Li SR, Zhang JM, et al. Meta-analysis on the epidemiology of gastroesophageal reﬂux disease in China [J]. World J Gastroenterol, 2022, 28(45): 6410-6420.
3	Wong WM, Lai KC, Lam KF, et al. Prevalence, clinical spectrum and health care utilization of gastro-oesophageal reflux disease in a Chinese population: a population-based study [J]. Aliment Pharmacol Ther, 2003, 18(6): 595-604.
4	Pohl H, Wrobel K, Bojarski C, et al. Risk factors in the development of esophageal adenocarcinoma [J]. Am J Gastroenterol 2013, 108(2): 200-207.
5	Wei WQ, Yang J, Zhang SW, et al. [Analysis of the esophageal cancer mortality in 2004 - 2005 and its trends during last 30 years in China] [J]. Zhonghua Yu Fang Yi Xue Za Zhi, 2010, 44(5): 398-402.
6	中华医学会消化病学分会胃肠动力学组，胃肠功能性疾病协作组，食管疾病协作组. 中国胃食管反流病诊疗规范 [J]. 中华消化杂志，2023, 43(9): 588-598.
7	Xiao YL, Zhou LY, Hou XH, et al. Chinese expert consensus on gastroesophageal reflux disease in 2020[J]. J Dig Dis, 2021, 22(7): 376-389.
8	Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease [J]. Am J Gastroenterol, 2013, 108(3): 308-328, quiz 329.
9	Zhang M, Pandolfino JE, Zhou X, et al. Assessing different diagnostic tests for gastroesophageal reflux disease: a systematic review and network meta-analysis [J]. Therap Adv Gastroenterol, 2019, 12:1756284819890537.
10	Zhang M, Chen M, Peng S, et al. The rome Ⅳ versus rome Ⅲ criteria for heartburn diagnosis: a comparative study [J]. United European Gastroenterol J, 2018, 6(3): 358-366.
11	Gerson LB, Kahrilas PJ, Fass R. Insights into gastroesophageal reflux disease-associated dyspeptic symptoms [J]. Clin Gastroenterol Hepatol, 2011, 9(10): 824-33.
12	Zhang MY, Tan ND, Li YW, et al. Esophageal symptoms versus epigastric symptoms: relevance for diagnosis of gastroesophageal reflux disease [J]. J Dig Dis, 2020, 21(12): 696-704.
13	Xiao YL, Peng S, Tao J, et al. Prevalence and symptom pattern of pathologic esophageal acid reflux in patients with functional dyspepsia based on the Rome Ⅲ criteria [J]. Am J Gastroenterol, 2010, 105(12): 2626-31.
14	Wang AJ, Liang MJ, Jiang AY, et al. Comparison of patients of chronic laryngitis with and without troublesome reflux symptoms [J]. J Gastroenterol Hepatol, 2012, 27(3): 579-85.
15	Peng S, Xiong LS, Xiao YL, et al. Prompt upper endoscopy is an appropriate initial management in uninvestigated chinese patients with typical reflux symptoms [J]. Am J Gastroenterol, 2010, 105(9): 1947-52.
16	Katz PO, Dunbar KB, Schnoll-Sussman FH, et al. ACG clinical guideline for the diagnosis and management of gastroesophageal reflux disease[J]. Am J Gastroenterol, 2022, 117(1): 27-56.
17	Gyawali CP, Yadlapati R, Fass R, et al. Updates to the modern diagnosis of GERD: Lyon consensus 2.0 [J]. Gut, 2024, 73(2): 361-371.
18	Lin Y, Li Y, Liang M, et al. Acid exposure time > 6% might not improve the therapeutic outcome in chinese gastroesophageal reflux disease patients [J]. J Neurogastroenterol Motil, 2021, 27(1): 55-62.
19	Xiao Y, Wu JCY, Lu CL, et al. Clinical practice guidelines for esophageal ambulatory reflux monitoring in Chinese adults [J]. J Gastroenterol Hepatol, 2022, 37(5): 812-822.
20	Sifrim D, Roman S, Savarino E, et al. Normal values and regional differences in oesophageal impedance-pH metrics: a consensus analysis of impedance-pH studies from around the world [J]. Gut, 2020, 9: gutjnl-2020-322627.
21	Penagini R, Sweis R, Mauro A, et al. Inconsistency in the diagnosis of functional heartburn: usefulness of prolonged wireless ph monitoring in patients with proton pump inhibitor refractory gastroesophageal reflux disease [J]. J Neurogastroenterol Motil, 2015, 21(2): 265-72.
22	Yadlapati R, Masihi M, Gyawali CP, et al. Ambulatory reflux monitoring guides proton pump inhibitor discontinuation in patients with gastroesophageal reflux symptoms: a clinical trial[J]. Gastroenterology, 2021, 160(1): 174-182.e1.
23	Xiao Y, Zhang S, Dai N, et al. Phase Ⅲ, randomised, double-blind, multicentre study to evaluate the efficacy and safety of vonoprazan compared with lansoprazole in Asian patients with erosive oesophagitis [J]. Gut, 2020, 69(2): 224-230.
24	Zhuang Q, Liao A, He Q, et al. The efficacy and safety of fexuprazan in treating erosive esophagitis: a phase Ⅲ, randomized, double-blind, multicenter study [J]. J Gastroenterol Hepatol, 2024, 39(4): 658-666.
25	Chen S, Liu D, Chen H, et al. The efficacy and safety of keverprazan, a novel potassium-competitive acid blocker, in treating erosive oesophagitis: a phase Ⅲ, randomised, double-blind multicentre study [J]. Aliment Pharmacol Ther, 2022, 55(12): 1524-1533.
26	Liu PP, Meng QQ, Lin H, et al. Radiofrequency ablation is safe and effective in the treatment of Chinese patients with gastroesophageal reflux disease: a single-center prospective study [J]. J Dig Dis, 2019, 20(5): 229-234.
27	Hu JN, Chen SF, Jia XY, et al. Two-year outcomes of anti-reflux mucosectomy in treating gastroesophageal reflux disease: a Chinese prospective cohort study [J]. J Dig Dis, 2023, 24(11): 611-618.
28	Shen S, Yu G, Guo X, et al. The long-term efficacy of transoral incisionless fundoplication with medigus ultrasonic surgical endostapler (MUSE) for gastroesophageal reflux disease [J]. Esophagus, 2023, 20(3): 581-586.
29	Xiao Y, Liang M, Peng S, et al. Tailored therapy for the refractory GERD patients by combined multichannel intraluminal impedance-pH monitoring [J]. J Gastroenterol Hepatol, 2016, 31(2): 350-354.
30	Tao J, Xiao YL, Chen MH, et al. [Changes of intercellular spaces of esophageal epithelium in patients with gastroesophageal reflux disease before and after esomeprazole treatment] [J]. Zhonghua Yi Xue Za Zhi, 2007, 87(6): 392-395.
31	Liu Z, Hu Y, Yu X, et al. Allergen challenge sensitizes TRPA1 in vagal sensory neurons and afferent C-fiber subtypes in guinea pig esophagus [J]. Am J Physiol Gastrointest Liver Physiol, 2015, 308(6): G482-G488.

[1]	Lili Gu, Fan Jiang. Survey and analysis of quality of screening prenatal ultrasound images in Anhui Province [J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2024, 21(07): 671-674.
[2]	Yan Zhang, Shaoling Yuan, Zehong Shi, Xinyang Guo, Jinghua Niu. Causes of missed diagnosis of small renal masses by ultrasound [J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2024, 21(05): 500-504.
[3]	Yuefang Xu, Wang Liu, Miaotian Zeng, Yushu Guo. Clinical efficacy of polymyxin B and polymyxin E in the treatment of surgical multi-drug resistant infections Security analysis [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(06): 700-703.
[4]	Linjuan Zhao, Jie Lv, Wensheng Wang, Demao Ma, Tao Hou. Study on the effect of ultrasound guided resection of stellate and cylindrical lactation preserving areas with staining marks [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(06): 634-637.
[5]	Yu Wang, Fangquan Xu, Xuan Zhou, Xiaofeng Yao, Qiang Li. Improve the standardization of radical resection of differentiated thyroid cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(05): 473-476.
[6]	Hui Sun, Changlin Li. Key considerations and strategies for radical resection of differentiated thyroid carcinoma [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(05): 477-481.
[7]	Tenghua Zhang, Peizhong Shang, Xiaomei Wang, Xiaowu Li, Jin Wang, Jianjun Miao, Bing Liu. Three-step stratified treatment strategy for traumatic splenic rupture [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(05): 510-512.
[8]	Weizhou Wu, Qiongren Wang, Xiongyu Zhan, Mingxing Zheng, Yaxian Li. Multidisciplinary consultation on difficult cases in Guangdong Urological Association (Phase 16): sarcomatoid renal cell carcinoma of the left kidney [J]. Chinese Journal of Endourology(Electronic Edition), 2024, 18(05): 525-529.
[9]	Guihu Weng, Yueze Liu, Taiping Zhang. Progress and controversies in the treatment of pancreatic neuroendocrine neoplasm [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(05): 602-606.
[10]	Junhua Wang, Ruixuan Wang. Current status and treatment strategy of neoadjuvant chemotherapy for pancreatic cancer [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(05): 640-643.
[11]	Department of Medical Administration of National Health Commission. Guidelines for diagnosis and treatment of primary liver cancer (2024) [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(04): 407-449.
[12]	Jing Zhao, Jiaxin Zhang, Yan Gao, Xisheng Xie. Progress of research on minimal change disease in its pathogenesis and treatment [J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2024, 13(04): 207-212.
[13]	Peipei Xi, Jiajun Zhou. Progress in research of sarcopenia in patients with chronic kidney disease: pathogenesis, diagnosis, and treatment [J]. Chinese Journal of Clinicians(Electronic Edition), 2024, 18(05): 491-495.
[14]	Ke Zhang, Zhanqi Yang, Wei Yan, Erming Zhang, Pingchao Xiang. Effect of continuous positive airway pressure on occurrence of cardiovascular and cerebrovascular events in patients with obstructive sleep apnea syndrome [J]. Chinese Journal of Clinicians(Electronic Edition), 2024, 18(05): 433-440.
[15]	Danhua Zhu, Fanggen Lu. Castleman disease characterized by ascites: report of sixteen cases [J]. Chinese Journal of Clinicians(Electronic Edition), 2024, 18(05): 462-473.

Please choose a citation manager

Content to export